Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $260.9 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 43.67% year-over-year to $260.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $260.9 million (up 43.67% YoY) and the FY2025 annual result came in at $219.7 million, up 32.19% from the prior year.
• Other Non-Current Liabilities was $260.9 million for Q1 2026 at Neurocrine Biosciences, up from $219.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $260.9 million in Q1 2026 and bottomed at $17.1 million in Q3 2022.
• A 5-year average of $119.4 million and a median of $120.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities dropped 7.51% — and 2023, when it jumped 301.17%.
• Neurocrine Biosciences' Other Non-Current Liabilities stood at $29.7 million in 2022, then jumped by 257.91% to $106.3 million in 2023, then jumped by 56.35% to $166.2 million in 2024, then surged by 32.19% to $219.7 million in 2025, then rose by 18.75% to $260.9 million in 2026.
• Business Quant data shows NBIX's Other Non-Current Liabilities at $260.9 million in Q1 2026, $219.7 million in Q4 2025, and $195.7 million in Q3 2025.